Alamar Biosciences ALMR

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Companies in Medical - Diagnostics & Research nearest Alamar Biosciences' size, closest first.

Company	Market cap	PE	Its 10y median PE	Fwd PE	P/S	Revenue growth	Net margin
ALMRAlamar Biosciences	$2.1B	n/m	n/a		n/m	n/m	n/m
CDNACareDx	$3.6B	33.4×	19.1×		7.8×	+34%	24.2%
VCYTVeracyte	$3.9B	34.2×	66.8×		6.9×	+17%	20.4%
BLLNBillionToOne	$5.1B	166×	151×		12.8×	+90%	9.5%
LNTHLantheus	$6.5B	24.2×	24.0×		4.2×	+2%	17.7%
CAICaris Life Sciences	$9B	86.5×	73.7×		9.1×	+85%	10.6%
NRCNRC Health	$485.1M	87.7×	35.1×		3.5×	−0%	4.2%
BIOBio-Rad Laboratories	$9.9B	44.8×	30.8×		3.8×	+1%	8.6%
RVTYRevvity	$17.7B	75.6×	34.8×		6.1×	+4%	8.2%
MEDPMedpace	$18.7B	39.2×	34.5×		6.7×	+25%	17.7%
Peer median	$6.5B	44.8×	34.8×		6.7×	+17%	10.6%

Investors we follow who held Alamar Biosciences at the end of Jun 30, 2026, from their 13F filings.

• Cathie WoodARK Investment Management0.2% of portfolionew

Each number over time

• Revenue
• EPS
• Free cash flow
• Shares outstanding

Its groups

• Medical - Diagnostics & Research
• Healthcare

Industry

Medical - Diagnostics & Research

Sector

Healthcare